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Abstract   
Formation of nitric oxide (NO) by the endothelial NO-synthase (eNOS) is a central 
process in the homeostatic regulation of vascular functions including blood pressure 
regulation and fluid shear stress exerted by the flowing blood is a main stimulus of 
eNOS activity. Previous work has identified several mechanosensing and -transducing 
processes in endothelial cells, which mediate this process and result in the stimulation 
of eNOS activity through phosphorylation of the enzyme via various kinases including 
AKT. How the initial mechanosensing and signaling processes are linked to eNOS 
phosphorylation is unclear. In human endothelial cells, we demonstrated that protein 
kinase N2 (PKN2), which is activated by flow through the mechanosensitive cation 
channel Piezo1 and Gq/G11-mediated signaling, as well as Ca2+ and PDK1, plays a 
pivotal role in this process. Active PKN2 promoted phosphorylation of human eNOS at 
serine 1177 and at a newly identified site, serine 1179. These phosphorylation events 
additively led to increased eNOS activity. PKN2-mediated eNOS phosphorylation at 
serine 1177 involved phosphorylation of AKT synergistically with mTORC2-mediated 
AKT phosphorylation while active PKN2 directly phosphorylated human eNOS at 
serine 1179. Mice with induced endothelium-specific deficiency of PKN2 showed 
strongly reduced flow-induced vasodilation and developed arterial hypertension 
accompanied by reduced eNOS activation. These results uncover a central 
mechanism that couples upstream mechanosignaling processes in endothelial cells to 




Endothelial cells are located at the interface between the blood and the vessel wall and 
are centrally involved in autoregulatory processes, which control vascular tone and 
homeostasis. Nitric oxide (NO) produced by endothelial NO-synthase (eNOS) plays a 
critical role in these regulatory processes by promoting vascular relaxation and by 
modulating vascular inflammation and adaptation to physiological and 
pathophysiological stimuli (1-3). The activity of eNOS is regulated by transcriptional 
and post-transcriptional mechanisms. Regulation of eNOS activity by fluid shear stress 
exerted by the flowing blood is one of the major mechanisms controlling basal activity 
of eNOS. Multiple studies have shown that the eNOS-mediated NO formation in 
response to sustained flow involves phosphorylation of the enzyme (3-5), and the two 
best-described residues of human eNOS phosphorylated in response to flow are serine 
633 and serine 1177 (4, 6-9). Protein kinase A (PKA) has been reported to be the major 
enzyme mediating the phosphorylation of serine 633 (8, 10-12), and AKT has been 
described as the major protein kinase responsible for flow-induced phosphorylation of 
serine 1177 (6, 7). Later, other related protein kinases, including AMP-activated kinase 
(AMPK) and PKA have been reported to be also able to mediate flow-induced  eNOS 
phosphorylation at serine 1177 (4, 5, 13, 14).  
Flow-induced regulation of AKT-dependent eNOS phosphorylation is mediated 
by the endothelial mechanosensitive cation channel Piezo1, which is activated by fluid 
shear stress and promotes release of ATP from endothelial cells which results in the 
activation of the Gq/G11-coupled purinergic P2Y2 receptor (15). Receptor activation 
induces downstream signaling processes resulting in the stimulation of AKT activity 
and the subsequent phosphorylation of human eNOS at serine 1177, which then leads 
to increased NO formation (16). An important role of AKT1 in flow-induced eNOS 
phosphorylation and activation has been indicated by knock-down studies in vitro (17) 
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as well as in endothelium-specific Akt1-deficient mice, which show reduced phos-
phorylation of the corresponding serine residue of mouse eNOS, reduced circulating 
NO levels and increased blood pressure (18). How the upstream mechanosignaling 
processes are linked to AKT-dependent eNOS activation is, however, not clear. It has 
been shown that phosphoinositide-3-kinase (PI-3-kinase) activity plays a role upstream 
of AKT also in flow-induced endothelial processes (6, 7, 19). However, maximal 
activation of AKT requires not only binding of the PI-3-kinase product phosphatidyl-
inositol-3,4,5-trisphosphate (PIP3) to AKT but also phosphorylation of the enzyme at 
threonine 308 by the phosphoinositide-dependent protein kinase 1 (PDK1) as well as 
at serine 473 by other kinases such as mTOR complex 2 (mTORC2) or DNA-PK (19, 
20). The mechanisms involved in flow-induced phosphorylation and activation of AKT 
in endothelial cells are still unknown.  
 Protein kinases N (PKN) are serine/threonine kinases formerly known as protein 
kinase C-related kinases (PRKs), which consist of the three isoforms PKN1, PKN2 and 
PKN3 (21, 22). PKN2 shares with the other isoforms an N-terminal antiparallel coiled-
coil structure (HR1 domain) that binds to and is activated by Rho family GTPases (23-
25) and a C-terminal kinase domain that can be phosphorylated by phosphoinositide-
dependent protein kinase 1 (PDK1) promoting PKN activation (26, 27). In vitro studies 
in various cell types have involved PKN2 in the regulation of different cellular functions 
including cytoskeletal organization, cell migration as well as cell differentiation (28-32). 
Loss of PKN2 in mice results in morphogenetic and cardiovascular defects and is lethal 
at embryonic day 10.5 (33, 34). 
 Here we show that PKN2 plays a central role in flow-induced eNOS regulation 
by mediating phosphorylation of eNOS at serine 1177 via Akt and by direct 






Flow induces phosphorylation of human eNOS at serine 1177 and 1179 
In a mass spectrometry-based phosphoproteomic analysis of bovine aortic endothelial 
cells (BAECs), we found that eNOS is phosphorylated in response to laminar flow not 
only at serine 635 and 1179, which corresponds to human eNOS serine 633 and 1177, 
but also at serine 1181, which corresponds to human eNOS serine 1179 (Fig. 1A and 
B). Increased phosphorylation of bovine and human eNOS at serine 1181 and 1179, 
respectively, could be validated in BAECs and human umbilical arterial endothelial 
cells (HUAECs) using a phospho-site-specific antibody (Fig. 1C and D). This antibody 
specifically recognized a phosphomimetic mutant of human eNOS in which serine 
1179 was replaced by aspartic acid (S1179D), while a phosphomimetic mutant of 
serine 1177 of eNOS (S1177D) was specifically recognized by the anti-phospho serine 
1177 antibody (Fig. 1E). Serine residue 1179 of human eNOS and the surrounding 
sequence are highly conserved in other species (Fig. 1A). Expression of the S1179D 
mutant of human eNOS resulted, similar to the S1177D mutant, in increased NO 
formation when expressed in endothelial cells after knockdown of endogenous eNOS 
(Fig. 1F and Suppl. Fig. 1). A phosphomimetic serine 1177 and 1179 double mutant 
(S1177D/S1179D) induced a significantly higher increase in NO formation than each 
of the single mutants (Fig. 1F). This additive effect indicates that both phosphorylation 
events act independently of each other. After knock-down of endogenous eNOS in 
HUAECs, re-expression of human eNOS mutants which cannot be phosphorylated 
anymore (S1177A and S1179A) only partially rescued flow-induced NO formation 
compared to cells in which wild-type eNOS was re-expressed, and a S1177A/S1179A 
double mutant showed a further reduced ability to rescue flow-induced NO formation 
(Fig. 1G). Similarly, carotid arteries from eNOS-/- mice, in which the S1177A and 
S1179A mutants of eNOS were re-expressed by AAV2-QuadYF-mediated 
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transduction only partially rescued flow-induced vasorelaxation compared to vessels 
which expressed wild-type eNOS (Fig. 1H). This indicates that, in addition to 
phosphorylation of serine 1177, human eNOS is also phosphorylated at serine 1179 
in response to flow and that serine 1179 phosphorylation contributes to the flow-
induced increase in eNOS activity. Flow-induced eNOS phosphorylation at serine 1179 
was not affected by knock-down of AKT1, the major isoform of AKT expressed in 
endothelial cells, whereas AKT1 knock-down strongly inhibited flow-induced eNOS 
phosphorylation at serine 1177 (Fig. 1I). Thus, flow-induced phosphorylation of human 
eNOS at serine 1179 occurs in an AKT-independent manner. 
 
PKN2 is activated by flow and mediates phosphorylation of eNOS at serine 1177 
and 1179 
In an attempt to identify protein kinases involved in flow-induced eNOS 
phosphorylation at serine 1179, we performed an siRNA-mediated knock-down of 25 
protein kinases highly expressed in human umbilical arterial endothelial cells 
(HUAECs) and determined the effect on flow-induced phosphorylation of eNOS at 
serine 1177 and 1179 (Fig. 2A and Suppl. Fig. 2A). Among the kinases whose knock-
down significantly reduced flow-induced eNOS phosphorylation at serine 1179 was 
PKN2 (Fig. 2A). An alternative siRNA directed against PKN2 blocked flow-induced 
eNOS phosphorylation at serine 1179 and at serine 1177 (Fig. 2B) as well as flow-
induced increases in NO levels in cellular supernatants as determined by 
measurement of nitrite/nitrate levels in HUAECs  (Fig. 2C). Corresponding effects were 
seen after PKN2 knock-down in BAECs (Fig. 2D and E). PKN2 is the major PKN 
isoform expressed in different endothelial cells followed by PKN1, whereas PKN3 
showed lower endothelial expression (Suppl. Fig. 3A). Knock-down of PKN1 
expression had no effect on flow-induced eNOS phosphorylation and NO formation in 
HUAECs (Suppl. Fig. 3C-D).  
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 To test whether PKN2 is activated by laminar flow in endothelial cells, we 
determined the effect of laminar shear stress on PKN2 kinase activity. Laminar flow 
increased PKN2 kinase activity as shown by an in vitro-kinase assay on 
immunoprecipitated PKN2 using myelin basic protein (MBP) as substrate (Fig. 2F).  
Within 5 minutes of applying laminar flow to endothelial cells, we found phosphorylation 
of PKN2 at threonine 816, which has been shown to result in PKN2 activation (27) (Fig. 
2G). Phosphorylation of PKN2 required high shear rates of at least 10 dynes/cm2 and 
lasted for at least 24 hours (Fig. 2H and I).  
 
Flow-induced PKN2 activation involves Piezo1, Gq/G11 and PDK1 but not PI-3-
kinase 
RhoA, a known regulator of PKN2 was not involved in flow-induced PKN2 activation 
as knock-down of RhoA did not affect flow-induced PKN2 phosphorylation (Suppl. Fig. 
4A). Since PDK1 has been shown to phosphorylate and thereby activate PKN2 (26, 
27, 35) and since knockdown of PDK1 inhibited flow-induced phosphorylation of 
human eNOS at serine 1179 to a comparable degree as knockdown of PKN2 (Fig. 2A), 
we tested its involvement in flow-induced PKN2 activation. Knock-down of PDK1 in 
fact blocked flow-induced PKN2 phosphorylation as well as phosphorylation of eNOS 
at serine 1177 and 1179 (Fig. 3A). The PDK1 activator PS48 induced a strong 
phosphorylation of PKN2 as well as of serine 1177 and 1179 of eNOS (Fig. 3B and C), 
and knock-down of PKN2 inhibited PS48-induced eNOS phosphorylation at serine 
1177 and 1179 (Fig. 3C). Similarly, also NO formation induced by PS48 was strongly 
inhibited by knock-down of PKN2 (Fig. 3D). This indicates that flow-induced PKN2 
activation resulting in eNOS phosphorylation is mediated by PDK1. 
 To understand the upstream regulation of PDK1 and PKN2 in flow-induced 
signaling, we tested the effect of knock-down or inhibition of known upstream 
mediators of flow-induced eNOS activation on flow-induced phosphorylation of PKN2.  
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Knock-down of Piezo1 inhibited phosphorylation of both, PDK1 and PKN2 as well as 
eNOS phosphorylation at serine 1177 and at serine 1179 (Fig. 3E), and the Piezo1 
activator Yoda1 induced phosphorylation of PDK1 and PKN2 (Fig. 3F). The effect of 
Piezo1 activation on PKN2 phosphorylation was blocked after suppression of PDK1 
expression (Fig. 3G). Flow induced activation of Piezo1 resulting in eNOS activation 
has been shown to involve release of ATP, activation of the endothelial P2Y2 receptor 
and subsequent Gq/G11-mediated signaling (15, 16). Knock-down of P2Y2 expression 
with a specific siRNA or pharmacological inhibition of Gq/G11 by YM-254890 (36) 
inhibited flow-induced phosphorylation of both, PDK1 and PKN2 (Fig. 3H and I). Thus, 
flow-induced activation of PDK1 and PKN2 involves Piezo1 and P2Y2/Gq/G11-mediated 
signaling. 
Piezo1 and Gq/G11-mediated signaling have been shown to mediate flow-
induced activation of the mechanosignaling complex consisting of PECAM-1, VE-
cadherin and VEGFR2 as well as PI-3-kinase and AKT (15, 16). We therefore tested 
the effect of inhibition of VEGFR2 by Ki8751 and of PI-3-kinase by wortmannin or 
LY294002 as well as the effect of an AKT1 knockdown on flow-induced 
phosphorylation of PDK1, PKN2 and eNOS. Inhibition of VEGFR2 and PI-3-kinase had 
no effect on flow-induced PDK1 and PKN2 phosphorylation whereas it blocked flow-
induced phosphorylation of eNOS at serine 1177 but not phosphorylation of eNOS at 
serine 1179 (Fig. 4A). Similar to inhibition of VEGFR2, and PI-3-kinase, knock-down 
of AKT1 did not affect PKN2 phosphorylation in response to flow (Fig. 4B). This 
indicated that the mechanosignaling complex and PI-3-kinase/AKT are not involved in 
flow induced activation of PDK1 and PKN2 downstream of Piezo1 and Gq/G11.  
We then tested whether the increase in [Ca2+]i induced by flow through Piezo1 
and Gq/G11-mediated signaling (16) is involved in flow-induced activation of PDK1 and 
PKN2. In fact, chelation of intracellular Ca2+ by BAPTA blocked flow-induced 
phosphorylation of PDK1 and PKN2 (Fig. 4C), and, in addition to the Piezo1 activator 
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Yoda1, also the Ca2+ ionophore ionomycin induced phosphorylation of PDK1 and 
PKN2 (Fig. 4D). Phosphorylation of PKN2 in response to ionomycin was blocked after 
suppression of PDK1 expression (Fig. 4E). These data indicate that flow-induced 
PKN2 phosphorylation is mediated by PDK1 in a manner depending on Piezo1, 
ATP/P2Y2, Gq/G11 and Ca2+ but independently of PI-3-kinase (Fig. 4F).  
 
PKN2 mediates eNOS activation by AKT-dependent phosphorylation of serine 
1177 and direct phosphorylation of serine 1179    
Although activation of PDK1 and PKN2 appears to occur independently of flow-induced 
activation of the mechanosignaling complex and PI-3-kinase, which have been shown 
to be required for flow-induced phosphorylation of eNOS at serine 1177 by AKT (16, 
37), knock-down of PKN2 and PDK1 blocked flow-induced eNOS phosphorylation at 
serine 1177 (Figs. 2B and 3A). We therefore tested whether AKT activation by flow 
requires PKN2 and PDK1. As shown in Fig. 5A and B, knock-down of PKN2 and of 
PDK1 had no effect on flow-induced AKT phosphorylation at serine 473 but strongly 
inhibited AKT phosphorylation at threonine 308. Flow-induced AKT phosphorylation at 
serine 473 was instead blocked by knock-down of the mTORC2 component Rictor (Fig. 
5C). Thus, PDK1 and PKN2 act upstream of AKT by mediating phosphorylation at 
threonine 308 but not of serine 473, which is phosphorylated via mTORC2. Consistent 
with this, the PDK1 activator PS48 induced AKT phosphorylation at threonine 308 but 
not at serine 473, and this effect was blocked after knockdown of PKN2 (Fig. 5D). In 
addition, expression of a constitutively active mutant of PKN2 induced phosphorylation 
of eNOS both at serine 1177 and serine 1179, however, only phosphorylation at serine 
1177 was strongly inhibited after knockdown of AKT1 (Fig. 5E). Similarly, the increased 
NO production induced by expression of constitutively active PKN2 was partially 
reduced by knock-down of AKT1 as well as by overexpression of the AKT1 phospho-
site mutant T308A (Fig. 5F and G). These data indicate that PKN2 is involved in flow-
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induced AKT phosphorylation at threonine 308 and that AKT mediates the PKN2-
induced eNOS activation at serine 1177. 
 As expected from the initial observation that flow-induced phosphorylation of 
human eNOS at serine 1179 does not involve AKT (Fig. 1H), AKT1 knock-down had 
no effect on eNOS phosphorylation at serine 1179 induced by active PKN2 but 
inhibited PKN2-induced eNOS phosphorylation at serine 1177 (Fig. 5E). To test 
whether PKN2 can directly phosphorylate eNOS at serine 1179, we first tested whether 
PKN2 and eNOS physically interact. When PKN2 was precipitated from endothelial 
cells under static conditions, no signal could be detected with an anti-eNOS-antibody 
in the precipitate. However, after 15 minutes of laminar flow, a relatively strong eNOS 
signal was seen in the PKN2 precipitate (Fig. 6A). When recombinant eNOS was 
incubated together with purified PKN2 in the presence of ATP, strong phosphorylation 
of serine 1179 but not of serine 1177 was observed (Fig. 6B and C). These data 
indicate that PKN2 can interact with eNOS and phosphorylate serine 1179 of eNOS, 
suggesting that PKN2 induces eNOS activation in response to flow through AKT-
dependent phosphorylation of serine 1177 as well as by direct phosphorylation of 
eNOS at serine 1179 (Fig. 6D). 
 
 
Endothelial PKN2 deficiency results in hypertension and loss of flow-induced 
vasodilation 
To test whether PKN2-mediated endothelial eNOS activation is physiologically 
relevant, we generated mice with tamoxifen-inducible endothelium-specific PKN2 
deficiency (Tek-CreERT2;Pkn2fl/fl, herein referred to as EC-Pkn2-KO) (Fig. 7A). 
Precontracted aortic segments from induced EC-Pkn2-KO mice showed normal 
relaxation in response to acetylcholine (Fig. 7B). However, endothelial loss of PKN2 
resulted in a strong reduction of flow-induced dilation of precontracted mesenteric 
vessels (Fig. 7C). We then tested the effect of an acute induction of endothelial Pkn2 
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deficiency on telemetrically recorded blood pressure in conscious mice. Treatment of 
wild-type mice with tamoxifen resulted in a transient increase in arterial blood pressure 
(Fig. 7D). However, induction of endothelial Pkn2 deficiency led to a sustained increase 
in arterial blood pressure by 20 mmHg. A very similar increase in blood pressure was 
seen after induction of Cdh5-CreERT2;Pkn2flox/flox mice (Suppl. Fig. 5A and B). 
Induction of endothelial Pkn1 deficiency had no effect on the blood pressure (Fig. 7D) 
consistent with a lack of any effect of Pkn1 knock-down on flow-induced eNOS 
activation in vitro. In parallel to the increase in arterial blood pressure after induction of 
endothelium-specific Pkn2 deficiency, we observed a reduced phosphorylation of 
murine mesenteric artery eNOS at serine 1176 and serine 1178, corresponding to 
serine 1177 and serine 1179 in human eNOS, respectively (Fig. 7E). The reduced 
phosphorylation of eNOS in mice with induced endothelial PKN2 deficiency was 
accompanied by a decrease in plasma nitrite/nitrate levels (Fig. 7F). These data 
indicate that the acute loss of PKN2-mediated signaling in the endothelium results in 




The regulation of eNOS is a complex process involving different upstream stimuli and 
several mechanisms including posttranslational modifications (3, 4, 9). Fluid shear 
stress exerted by the flowing blood is one of the most important stimuli of eNOS activity 
which is centrally involved in basal control of vascular functions such as vascular tone 
and blood pressure. In the past, two major pathways were described to regulate eNOS 
activity in response to fluid shear stress. One is initiated by flow-induced release of 
adrenomedullin and subsequent activation of cAMP formation and protein kinase A 
through the adrenomedullin receptor resulting in phosphorylation of human eNOS at 
serine 633 (4, 8, 9, 12, 38). The other one is initiated by the release of ATP, which, 
through activation of P2Y2 receptors and the Gq/G11-mediated signaling pathway, 
results in activation of AKT and phosphorylation of human eNOS at serine 1177 (3, 4, 
6, 7, 16). Upstream regulation of both pathways has been shown to involve activation 
of the mechanosensitive cation channel Piezo1 (12, 15). While previous research had 
shown that flow-induced Gq/G11-mediated activation of AKT involves a 
mechanosignaling complex including VEGFR2 (16, 37), the direct mechanism of flow-
induced AKT activation has remained unclear. Here we show that AKT activation and 
subsequent eNOS phosphorylation at serine 1177 in response to flow required PKN2 
and that PKN2 in addition also leads to phosphorylation of eNOS at serine 1179. We 
also demonstrate that these effects are additive and we identified the upstream 
regulation of flow-induced PKN2 activation, which involved P2Y2- and Gq/G11-mediated 
increases in intracellular Ca2+ and subsequent PDK1 activation (Fig. 6D). The fact that 
acute loss of endothelial PKN2 leads to reduced eNOS activity, reduced flow-induced 
vasodilation and to hypertension in vivo indicates that this new PKN2-mediated 
signaling pathway in endothelial cells is constantly activated to mediate fluid shear 
stress-induced endothelial NO formation and vasodilation.  
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The central role of AKT in eNOS phosphorylation and activation is well established (6, 
7, 39), and viral transduction of a constitutively active AKT resulted in increased NO 
release and enhanced blood flow in vivo (40). Similar results were observed after 
endothelial cell-specific expression of an active version of AKT, which resulted in 
increased NO production (41). That AKT-mediated regulation of eNOS activity in vivo 
is mediated by phosphorylation of eNOS at serine 1177 was further supported by the 
observation that the corresponding phosphomimetic murine eNOS mutant S1176D can 
rescue the vascular phenotype observed in AKT1-deficient mice (39) as well as by the 
finding that endothelial cell-specific AKT1-deficient mice have reduced plasma NO 
levels, reduced phosphorylation of murine eNOS at serine 1176 in blood vessels as 
well as increased blood pressure (18). The mechanism by which AKT is activated by 
fluid shear stress has however remained unclear. A general requirement for AKT 
activation is the stimulation of phosphoinositide-3-kinase (PI-3-K), leading to PtdIns-
3,4,5-P3 (PIP3) formation which recruits AKT to the membrane through interaction with 
its PH domain (19, 20, 42). Consistent with this, fluid shear stress has been shown to 
induce activation of PI-3-kinase (37, 43). However, full activation of the AKT kinase 
activity requires phosphorylation of AKT at threonine 308 in the catalytic domain of the 
kinase, which typically involves PDK1 (19, 20, 44, 45) as well as phosphorylation of 
serine 473 in a C-terminal hydrophobic motif mainly mediated by mTORC2 (46, 47). 
Whether flow-induced endothelial AKT activation also involved PDK1- and mTORC2-
mediated phosphorylation was however unknown. Our data clearly show that 
disruption of mTORC2 by suppression of Rictor expression blocked flow-induced AKT 
phosphorylation at serine 473, but not at threonine 308. Flow-induced AKT 
phosphorylation at threonine 308 was blocked after knock-down of PDK1 and also of 
PKN2, whereas in both cases phosphorylation of serine 473 was unaffected. The 
specific phosphorylation of AKT at threonine 308 could be mimicked by the PDK1 
activator PS48, which also induced a strong phosphorylation of PKN2. Interestingly, 
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the effect of PS48 on AKT phosphorylation at threonine 308 was blocked after knock-
down of PKN2. This indicated that flow-induced AKT phosphorylation at threonine 308 
through PDK1 does not occur directly, but is mediated by PKN2 in endothelial cells 
exposed to flow. This function of PKN2 to mediate PDK1-induced phosphorylation of 
AKT at threonine 308 is consistent with several in vitro reports showing that PKN2 is a 
substrate of PDK1 and can be activated through PDK1-mediated phosphorylation (26, 
27, 35). In addition, there is also evidence that PKN2 and AKT1 interact (48, 49) and 
that PKN2 can activate AKT (32). We conclude that flow-induced activation of 
endothelial AKT involves PI-3-kinase/mTORC2-mediated phosphorylation at serine 
473 and phosphorylation at threonine 308 through an atypical mechanism involving 
PKN2 which is activated by PDK1 (Fig. 6D). 
 PKNs have been described to be activated by binding to members of the Rho 
family of GTPases through a Rho-binding motif known as the HR1 domain (23-25). 
However, we did not find any evidence for a role of Rho-GTPases in flow-induced 
endothelial PKN2 activation. This is consistent with published data that RhoA is not 
activated in response to acute flow in endothelial cells (50). We rather found that flow-
induced PKN2 activation in endothelial cells is mediated by PDK1. Interestingly, this 
PDK1-mediated PKN2 activation was independent of PI-3-kinase and VEGFR2, as 
their inhibition did not affect flow-induced phosphorylation of PKN2 and PDK1 while 
inhibition of PI-3-kinase and VEGFR2 blocked flow-induced AKT phosphorylation at 
serine 473 (16, 51). This indicates that flow-induced activation of PDK1/PKN2 occurs 
independently of the mechanosignaling complex consisting of PECAM-1, VE-cadherin 
and VEGFR2, which mediates flow-induced activation of PI-3-kinase (37). Instead we 
found that flow-induced activation of PKN2 was blocked after knock-down of Piezo1 
and P2Y2, inhibition of Gq/G11 and chelation of intracellular Ca2+ using BAPTA, while it 
could be induced by the Piezo1 activator Yoda1 and by the calcium ionophore 
ionomycin. This strongly indicates that flow-induced activation of PDK1/PKN2 is a 
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calcium-mediated process downstream of Piezo1 and Gq/G11 (Fig. 6D). This is 
consistent with earlier data showing that Ca2+ can activate PDK1 (52) and that Ca2+-
induced phosphorylation of Akt at threonine 308 involves PDK1 (53).  
 Serine 1177 is one of the most extensively studied phosphorylation sites of 
human eNOS and several in vitro studies have shown that a phospho-mimetic mutant, 
in which serine 1177 is replaced by aspartic acid (S1177D), has an increased basal 
activity (6, 7). Conversely, endothelial cells expressing the phosphosite mutant 
S1177A show reduced flow-induced NO formation (12). Knock-in mice expressing the 
corresponding phosphomimetic S1176D mutant of mouse eNOS show increased 
endothelium-dependent vasodilation, whereas mice expressing the phosphosite 
mutant S1176A have reduced endothelium-dependent vasodilation and an increase in 
blood pressure (54-56). While this represents strong evidence for a role of serine 1177 
phosphorylation in the regulation of human eNOS activity in vitro and in vivo, a recent 
in vitro study has challenged this view and found that eNOS phosphorylation at serine 
1177 does not correlate with increased activity of the enzyme (57). The reason for this 
discrepancy is still unclear, but flow-induced effects were not analyzed in this study. 
Mechanistically it has been suggested that the C-terminal region of the enzyme to 
which serine 1177 is located has an autoinhibitory function and that phosphorylation at 
serine 1177 reduces this autoinhibition (58-60). Our data show that in addition to serine 
1177 also serine 1179 in human eNOS as well as the corresponding serine residue in 
bovine eNOS is phosphorylated in response to flow. This serine residue is highly 
conserved in different species, and its phosphorylation might have been overseen in 
previous analyses. We show that serine 1177 and 1179 are phosphorylated 
independently of each other by different mechanisms involving the classic PI-3 
kinase/mTORC2/AKT pathway as well as a new mechanism mediated by PKN2. 
Importantly, both phosphorylation events promote eNOS activation in an additive 
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fashion. Whether the additivity of the effects of both phosphorylations on eNOS activity 
is due to the same of different mechanisms is currently not clear. 
 Our results identify serine 1179 of human eNOS as an additional 
phosphorylation site, which, together with the well-established serine 1177 
phosphorylation, additively regulates eNOS activity. Both serine residues are 
phosphorylated in response to fluid shear stress through different pathways, a PI-3-
kinase- and mTORC2-dependent pathway, resulting in AKT phosphorylation at serine 
473 to induce serine 1177 phosphorylation of eNOS as well as through an independent 
pathway involving Ca2+, PKD1 and PKN2, resulting in phosphorylation of serine 
residue serine 1179 of human eNOS. PKN2 also plays an important role in serine 1177 
phosphorylation as it phosphorylates AKT at threonine 308 in response to flow and 
thereby promotes AKT-dependent serine 1177 phosphorylation of human eNOS. Thus, 
our data favor a model, in which PKN2 integrates different flow-induced signaling 
pathways to link them to phosphorylation-dependent eNOS activation. It will be 
interesting to see whether the PKN2-mediated endothelial signaling process is affected 
in pathological situations, in which eNOS activity is impaired, and whether PKN2 is 






Reagents. Acetylcholine, phenylephrine, sodium nitroprusside (SNP), BAPTA-AM 
(1,2-Bis (2-aminophenoxy) ethane -N,N,N′,N′- tetraacetic acid tetrakis(acetoxymethyl 
ester)), PS48, ionomycin, KN93, wortmannin, LY294002, Ki8751 and tamoxifen were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). YM-254890 was from FUJI FILM 
Wako Chemicals (cat. no.: 257-00631). Yoda1 was from Maybridge (cat. no.: 
SPB07298). Antibodies directed against phosphorylated eNOS (mouse S1176, human 
S1177, and bovine S1179; cat. no.: 9571), phosphorylated AKT (S473; cat. no.: 4060), 
phosphorylated AKT (T308; cat. no.: 13038), AKT (cat. no.: 9272), phosphorylated 
PDK1 (S241; cat. no.: 3438), PDK1 (cat. no.: 5662), phosphorylated PKN2 (T816; cat. 
no.: 2611), PKN2 (cat. no.: 2612), RhoA (cat. no.: 2117), Rictor (cat. no.: 2114), 
GAPDH (cat. no.: 2118) and Tubulin (cat. no.: 2521S) were obtained from Cell 
Signaling Technology. Antibody directed against phosphorylated eNOS (mouse 
S1178, human S1179, and bovine S1181; cat. no.: PA5-64532) was obtained from 
Thermofisher scientific. Anti-eNOS (cat. no.: 610296) and PKN1 (cat. no.: 610687) 
antibody were purchased from BD Biosciences). Anti-P2Y2 antibody was from 
Alomone Labs (cat. no.: APR-010). Anti-PIEZO1 antibody was from Proteintech (cat. 
no.: 15939-1-AP).  
 
Primary cells. Human umbilical artery endothelial cells (HUAEC) and bovine aortic 
endothelial cells (BAEC) were purchased from Provitro AG and cultured in EGM-2 MV 
medium (Lonza, Basel, Switzerland). RFL-6 rat fibroblast cells (CCL-192) were 
purchased from American Type Culture Collections (ATCC, Manassas, VA, USA) and 




siRNA-mediated knockdown. Endothelial Cells were transfected with siRNA using 
Opti-MEM (Thermo Fisher) and Lipofectamine RNAiMAX (Invitrogen) as described 
previously (16). siRNAs used for screening were pools of three siRNA directed against 
non-receptor tyrosine kinase which show high expression in HUAEC and BAECs and 
were obtained from Sigma-Aldrich. The targeted sequences are shown in Suppl. Tab. 
1. Other siRNAs used were against the following sequences: 5-
GTGTTTGGTCTCAAGGACT-3 and 5-GTGTCTACTTCCTGCTCTT-3 (PIEZO1), and 
5-CCCTTCAGCACGGTGCTCT-3’, 5’-CTGCCTAGGGCCAAGCGCA-3 (P2RY2). The 
PDK1 esiRNA (#EHU079981), Rictor esiRNA (#EHU076781) and control siRNAs 
(#SIC001) were purchased from Sigma-Aldrich. 
 
Shear stress assays. Endothelial cells were seeded on µ-Slide I Luer (Ibidi, 80176) 
and laminar flow was applied on confluent monolayers using the Ibidi pump system 
chamber (ibidi, Germany). The constant wall shear stress (τ) is given by τ = η x 131.6 
φ; η: viscosity of the medium; φ: flow rate (according to manufacturer’s instructions).  
 
Western blotting. Endothelial cells and mesenteric arteries were lysed in RIPA buffer 
freshly supplemented with protease and phosphatase inhibitors (PhosSTOPTM, 
Roche). Total cell lysates subjected to SDS-PAGE electrophoresis and transferred to 
PVDF membranes. After blocking with 5% BSA for 1 hour, the membranes were 
incubated with primary antibodies overnight at 4°C. The membranes were incubated 
with HRP-conjugated secondary antibodies for 1 hour at RT (Cell Signaling, dilution 
1:3,000) followed by chemiluminescence detection using ECL substrate (Pierce) 
according to the manufacturer’s protocol. The intensities of protein bands were 




In vitro kinase and phosphorylation assay. Kinase activity was determined by 
performing an in vitro kinase assay (61). Briefly, endothelial cells were lysed in RIPA 
buffer containing protease inhibitors (complete protease inhibitor cocktail, Roche) and 
phosphatase inhibitors (PhosSTOPTM, Roche), and after centrifugation (30.000 x g, 15 
min) the supernatant was incubated with 3 µg of the anti-PKN2 antibody overnight at 
4 °C on a rotating platform. Thereafter, 30 µl of protein A/G-Sepharose beads pre-
equilibrated in RIPA buffer were added and incubated for 1 hour at 4 °C. A/G-
Sepharose beads were then collected by centrifugation at 3.500 x g for 1 min and were 
washed 3 times and resuspended in washing buffer (20 mM Tris-HCl [pH7.4], 10 mM 
MgCl2). Pellets were resuspended in 20 µl of kinase buffer (20 mM Hepes, pH 7.4, 10 
mM MgAc, 1 mM dithiothreitol, 50 μM ATP, 20 μCi of [γ-32P]‐ATP (Hartmann Analytic, 
Germany), together with 1 μg of MBP (cat.no.: C1416, Santa Cruz Biotechnology Inc.) 
as substrate for 30 min at room temperature. To stop the reaction, SDS-PAGE loading 
buffer was added. The reaction mixture was separated by SDS-PAGE and 32P‐labeled 
proteins were visualized by autoradiography. For in vitro eNOS phosphorylation by 
PKN2, purified full-length human eNOS (cat. no.: ALX-201-853-0010, Enzo Life 
Sciences) and PKN2 (P71-10G-05, SignalChem) were mixed and incubated for 30 min 
at 30°C with 10 μCi of [γ-32P]‐ATP in 20 μl of kinase buffer. All reactions were 
terminated by adding SDS-PAGE loading buffer. Proteins were separated by SDS-
PAGE, and the gels were stained with Coomassie. The radioactivity was analyzed by 
autoradiography. Alternatively, in vitro eNOS phosphorylation by PKN2 was detected 
by immunoblotting by using the anti-phospho-eNOS S1179 antibody. 
 
Animal models. All mice were backcrossed onto a C57BL/6N background at least 8 
to 10 times, and experiments were performed with littermates as controls. Male and 
female animals (8–12 weeks old) were used unless stated otherwise. Mice were 
housed under a 12-hour light- dark cycle, with free access to food and water and under 
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specific pathogen-free conditions unless stated otherwise. The endothelium-specific 
Cre transgenic lines Tek-CreERT2 and Cdh5-CreERT2 have been described 
previously (62, 63). Embryonic stem (ES) cells heterozygous for a targeted allele of 
Pkn1 or Pkn2, which, after removal of a cassette flanked by FRT-sites, allows for Cre-
mediated recombination, have been purchased from KOMP repository (The Knockout 
Mouse Project, Davis, CA 95616 USA). ES cell clones were injected into C57BL/6 
blastocysts and were transferred to pseudo-pregnant females. Chimeric offspring were 
bred with C57BL/6 mice to produce heterozygous animals. The germ line transmission 
was confirmed in the F1 generation using a PCR genotyping strategy. In order to 
remove the selection cassette, mice were crossed to Flp-deleter mice (64) and were 
subsequently crossed with Tek-CreERT2 mice and Cdh5-CreERT2 mice to obtain 
animals with inducible endothelium-specific deficiency (EC-Pkn1-KO or EC-Pkn2-KO). 
eNOS-/- mice (B6.129P2-Nos3tm1Unc/1) were obtained from the Jackson Laboratories 
(Bar Harbor, ME, USA). 
 
Determination of nitrate and nitrite (NOx) and cGMP levels. Nitrate and nitrite 
(NOx) levels were measured as described previously (12). In brief, blood collected by 
venous puncture was immediately centrifuged at 6,800 g for 5 minutes at 4°C, and 20 
μl plasma was used for nitrate measurement. For experiment to determine flow-
induced nitrate release from endothelial cells, cells were plated on culture glass of the 
BioTech-Flow viscometer chambers (MOS Technologies). Cells were starved in 
serum-free medium for 6 h and were exposed to laminar flow for 30 min. Nitrate and 
nitrite production was measured based on nitrite and nitrate accumulation in the 
medium and plasma using a nitrate/nitrite fluorometric assay kit from Cayman 
Chemical according to the manufacturer’s instructions.  
Cyclic GMP levels were measured using the RFL-6 reporter cell assay as 
described (65). RFL-6 cells were grown to confluence in 6-well plates and washed 
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twice in Locke’s solution (154 mM NaCl, 5.6 mM KCl, 2 mM CaCl2, 1 mM MgCl2, and 
10 mM HEPES) containing 0.3 mM 3-isobutyl-1-methylxanthine (IBMX) before the 
experiment. RFL-6 cells were incubated with supernatants of HUAECs expressing 
control vector, wild-type eNOS or mutants of eNOS in the absence or presence of L-
NAME (1 µM). Thereafter, the incubation was stopped by the addition of ice-cold 50 
mM sodium acetate buffer (pH 4.0). The cells were then lysed and cyclic GMP 
concentration was determined using the cGMP assay kit according to the 
manufacturer’s instructions (Abcam, Cambridge, MA, USA, Cat. #ab65356). 
 
Wire myography. Two weeks after the last tamoxifen injection, mice were sacrificed 
by CO2 inhalation. Intact first order mesenteric arteries (2 mm) were isolated from the 
mesentery and mounted on a conventional myograph setup (610-M, Danish Myo 
Technology) and kept in Krebs solution (118.1 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 
1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, 9.3 mM glucose, and 0.026 mM 
EDTA). Arterial segments were distended to the diameter at which maximal contractile 
responses to 10 µM phenylephrine were observed (Dopt) (66). After a 30-min recovery 
period of normalization, the contractile and relaxation responses to the indicated 
agonists were tested. All arterial segments were allowed 30 min of recovery after 
normalization. Endothelial integrity was checked, the segments which show lower than 
80% relaxation were excluded from experiment. 
 
Pressure myography. Pressure myograph experiments were performed as described 
previously (16). In brief, 10-14 days after tamoxifen injection, second order mesenteric 
arteries were removed from the mesentery and were mounted between 2 glass 
micropipettes seated in a pressure myograph chamber (Danish Myo Technology; 
114P). The temperature of the chamber was kept at a constant 37°C during the 
experiment. The mounted artery was initially pressurized to 20 mmHg under no-flow 
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conditions and incubated for 30 minutes. Pressure was then increased to 60 mmHg 
and the vessel was incubated for 10 minutes to allow it to reach a steady-state 
diameter. Arterial segments were contracted with 50 to 150 nM U46619 to 40% to 50% 
of the passive diameter. After reaching a stable baseline, flow was increased in a 
stepwise manner by changing the pressure of the inflow and outflow sides inversely, 
thereby creating a pressure difference inside the lumen of artery without altering the 
intraluminal pressure. The viability of the vessel was verified at the end of the 
experiment by dilating the vessel with acetylcholine (10 μM). Arteries showing less 
than 60% relaxation were considered damaged and were omitted from further analysis. 
Vasodilatation to flow was calculated as a percentage of the U46619-induced 
contraction as described previously (67) by the following equation: percentage of 
relaxation = 100 × (DF – DU46619)/(DPD– DU46619), where D represents the external 
diameter of the vessels; DF is the vessel diameter during flow; DU46619 is the diameter 
after U46619 contraction; and DPD is the passive diameter without any treatment. 
 
Telemetric blood pressure measurements. Measurements were performed in 
conscious, unrestrained mice with a radiotelemetry system (PA-C10; Data Sciences 
International) as described previously (12). Mice were caged with blinded identity and 
in random order.  
 
Lentiviral infection of cells. Human wild-type or mutant forms of eNOS, Akt1 and 
PKN2 were cloned into the lentiviral pLVX-IRES-ZsGreen1 expression vector 
(Clontech, Mountain View, CA, USA) and were transfected into HEK293T cells along 
with envelope plasmid pMD2.G and packaging plasmid psPAX2 using Lipofectamine™ 
3000 Transfection Reagent (Thermo fisher Scientific) according to the manufacturer's 
protocol. Following 48 hours, supernatants containing lentiviral particles were 
harvested and filtered through 0.45 µm low-protein binding durapore membrane 
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(Millex) to remove cell debris. HUAECs were previously transfected with siRNA against 
human eNOS or AKT using Opti-MEM and Lipofectamine RNAiMAX (Invitrogen). For 
lentiviral transduction, HUAECs were seeded in 6-well plates and the concentrated 
lentivirus was added. After 48 hours, cells were used for further analyses.  
 
AAV infection. Adeno-associated virus 2-QuadYF carrying the cDNA encoding eNOS 
WT, the S1177A and S1179A mutant of eNOS as well as EGFP were generated by 
Vectorbuilder (Cyagen Biosciences). 10-12 week-old eNOS-/- mice were anesthetized 
by isofluorane inhalation. Mice were given AAV2-QuadYF-eNOS WT, S1177A, 
S1179A or AAV2-QuadYF-EGFP (1 × 1011 viral genomes in 100 μl saline) by 
intravenous injection. 1 week after virus injection, carotid arteries were harvested to 
measure gene expression and flow-induced vasorelaxation using a pressure 
myography system.  
 
Expression analysis. Total RNA was isolated using an RNeasy Micro Kit (Qiagen), 
according to the manufacturer’s instructions. Reverse transcription (RT) was 
performed using the ProtoScript II Reverse Transcription kit (New England BioLabs, 
M0368S). The resulting cDNA was used as a template for quantitative PCR (qPCR) 
reactions using the LightCycler 480 Probe Master System (Roche), following the 
manufacturer’s protocol. The primer sequences are listed in Suppl. Tab. 2. The 
resulting Cq values were analyzed and normalized to the reference gene GAPDH. 
 
Proteomic and phosphoproteomic analysis. Samples were prepared as described 
earlier (Iring et al., 2019) with modifications. Cells were lyzed in 4% SDS, 100 mM Tris, 
pH 7.6 without protease inhibitor by 10 min boiling followed by sonication prior to 
removal of cell debris by centrifugation. Further, samples were labeled using reductive 
dimethylation as reported (68) and STAGE tipping of proteomic samples omitted. Using 
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MARMoSET (69), liquid chromatography/tandem mass spectrometry (LC/MS2) 
instrumentation parameters were extracted as well as summarized from raw data files 
and are included in the supplemental material. Peptide/spectrum matching and 
quantitation were performed using the MaxQuant suite of algorithms (70, 71) against 
the UniProt (72) mouse canonical and isoforms bovine data base (downloaded on 
2019/08/19; 46,707 entries) with parameters also included in the supplemental 
information. Intensity values of the phospho-sites shown were normalized to eNOS 
intensity and thus protein abundance in the proteome. 
 
Statistics. All statistical analysis was performed using the GraphPad Prism software 
v.6.07 from GraphPad Software Inc. (La Jolla, CA, USA). All experimental values are 
presented as means ± s.e.m. Statistical significance was tested using either an ANOVA 
or unpaired Student’s t-tests. Statistical analysis between two groups were performed 
with an unpaired two-tailed Student’s t-test, multiple group comparisons were analyzed 
with one-way ANOVA followed by Tukey’s post-hoc test, and comparisons between 
multiple experimental group at different time points were performed using two-way 
ANOVA followed by Bonferroni’s post-hoc test. A p-value of less than 0.05 was 
considered to be statistically significant. 
 
Study approval. All procedures involving animal care and use in this study were 
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Figure 1.  
Figure 1. Flow induces eNOS phosphorylation at serine 1177 and 1179. (A) eNOS 
amino acid sequence of different species. (B) Phosphorylation of eNOS serine 
residues of BAECs exposed to laminar flow (15 dynes/cm2) determined by LC-MS/MS. 
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Shown are the fold changes of the corrected ratios of flow versus static conditions 
(n=3). (C,D) BAECs (C) or HUAECs (D) were exposed to laminar flow (15 dynes/cm2). 
and total and phosphorylated eNOS was determined by immunoblotting. Graphs show 
the densitometric evaluation (n=3 independent experiments). (E) HEK293 cells 
expressing the indicated mutants of human eNOS were lyzed and analyzed by 
immunoblotting using phosphosite-specific. (F,G) Wild-type (WT) or mutated human 
eNOS were expressed by lentiviral transduction after siRNA mediated eNOS 
knockdown in HUAECs, and the nitrate/nitrite concentration in the cell culture medium 
was determined in the absence (F) or depending on flow (G). Expression of eNOS was 
analyzed by immunoblotting (F,G, lower panels) (n=3 independent experiments). (H) 
eNOS-/- mice were infected with AAV2-QuadYF virus transducing wild-type or mutant 
eNOS or EGFP. 7 days later, carotid arteries were isolated and flow-induced 
vasorelaxation was analyzed. The immunoblot demonstrates equal expression levels 
of different eNOS mutants. (I) HUAECs transfected with control siRNA or siRNAs 
directed against AKT1 were exposed to laminar flow (15 dynes/cm2). Total AKT and 
total and phosphorylated eNOS were determined by immunoblotting. Bar diagrams 
show the densitometric evaluation of blots (n=3 independent experiments). Data 
represent the mean ± SEM; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 (two-way ANOVA 
with Bonferroni’s post-hoc test (C, D, G, H; P-values in H describe difference compared 
to eNOS-WT), one-way ANOVA, with Tukey’s post-hoc test (F and I)). P-values in 1c 






Figure 2. PKN2 is activated by flow and mediates phosphorylation of eNOS at 
serine 1177 and 1179. (A) HUAECs were transfected with control siRNA or siRNAs 
directed against the indicated protein kinases and were kept under static conditions 
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(static) or were exposed to laminar flow (15 dynes/cm2) for 15 min. Shown is the ratio 
of flow-induced phosphorylation of eNOS at serine 1179 in cells transfected with 
control siRNA and an siRNA against a particular protein kinase. The plot shows the 
ranked average ratios of 3 independent experiments. (B-E) HUAECs (B,C) or BAECs 
(D, E) were transfected with control or siRNA against PKN2 and were exposed to 
laminar flow (15 dynes/cm2). Total and phosphorylated eNOS as well as PKN2 were 
determined by immunoblotting (B,D), or nitrate/nitrite levels were determined in the 
supernatants (C,E). Bar diagrams show the densitometric evaluation of blots (n=3 
independent experiments). (F-I) HUAECs were exposed to laminar flow (15 dynes/cm2, 
if not stated otherwise) for the indicated time periods. Thereafter, PKN2 was 
immunoprecipitated and its kinase activity was determined as described in the 
Methods section (F), or total as well as phosphorylated PKN2 was determined by 
immunoblotting (G-I). Bar diagrams show the densitometric evaluation of blots (n=3 
independent experiments). Data represent the mean ± SEM; *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, (two-way ANOVA with Bonferroni’s post-hoc test (A), one-way ANOVA, 









Figure 3. Flow-induced PKN2 activation involves Piezo1, Gq/G11 and PDK1. (A-I) 
HUAECs were transfected with control siRNA or siRNAs directed against PDK1 (A,G),  
PKN2 (C,D), Piezo1 (E), P2Y2 (H) or were left untransfected (B,F) or were pretreated 
without or with 100 nM of YM-254890 (YM) (I) for 30 min. Thereafter, cells were 
exposed to laminar flow (15 dynes/cm2) for 15 min or the indicated time periods 
(A,E,H,I) or to 5 µM of PS48 for 15 min or the indicated time periods (B-D) or to 1 µM 
of Yoda1 for 15 min or the indicated time periods (F,G). Phosphorylation or total 
amount of the indicated proteins was determined in lysates by immunoblotting (A-C, 
E-I), or the concentration of nitrate/nitrite was measured in the supernatant (D). Bar 
diagrams in A,C,F-I show the densitometric analysis of blots (n=3 independent 
experiments). Data represent mean ± SEM; *, P ≤ 0.05; **, P ≤ 0.01 ***, P ≤ 0.001 







Figure 4. Flow-induced PKN2 activation involves Ca2+ but not PI-3-kinase and 
AKT. (A-E) HUAECs were preincubated for 30 minutes with PI3K inhibitors 
wortmannin (100 nM), LY294002 (10 µM) or the VEGFR2 inhibitor Ki8751 (500 nM) 
(A) or with 20 µM of BAPTA-AM (C) or were transfected with control siRNA or siRNAs 
directed against AKT1 (B) or PDK1 (E) or were without pretreatment (D). Thereafter, 
cells were exposed to flow (15 dynes/cm2) for 15 min (A-C) or to 1 µM of ionomycin 
(D,E) for 15 min or the indicated time periods. Phosphorylation and total amount of the 
indicated proteins was determined in lysates by immunoblotting. Bar diagrams show 
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the densitometric analysis of blots (n=3 independent experiments). The control 
immunoblot for AKT1 in B is from the same experiment as the one shown in Fig. 1I. 
(F) Model of the mechanism mediating laminar flow-induced PKN2 activation resulting 
in eNOS phosphorylation and activation. Data represent mean ± SEM; *, P ≤ 0.05; **, 







Figure 5. PKN2 mediates phosphorylation of AKT at threonine 308 but not at 
serine 473. (A-G) HUAECs were transfected with control siRNA or siRNAs directed 
against PKN2 (A,D-G), PDK1 (B), Rictor (C) or AKT1 (E-G) and were then exposed to 
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laminar flow (15 dynes/cm2) for 15 min or the indicated time periods (A-C) or to 5 µM 
of PS48 for 15 min (D). Alternatively, a constitutively active mutant of PKN2 (PKN-CA) 
(E-G) as well as the indicated phosphosite mutants of AKT1 (G) were expressed by 
lentiviral transduction after siRNA-mediated knockdown of AKT1 (E,F) in HUAECs. 
Phosphorylation or total amount of the indicated proteins was determined in lysates by 
immunoblotting (A-E), or the concentration of nitrate/nitrite was measured in the 
supernatant (F,G). Bar diagrams in a-e show the densitometric evaluation of blots (n=3 
independent experiments). Control immunoblots for PKN2 and PDK1 knock-down 
efficiency in A, B and D are from the same experiments as those shown in Figs. 2B, 
3A and 3C, respectively. Data represent mean ± SEM; *, P ≤ 0.05; **, P ≤ 0.01 ***, P 
≤ 0.001 (one-way ANOVA, with Tukey’s post-hoc test (A-F), two-way ANOVA with 







Figure 6. PKN2 mediates eNOS activation by direct phosphorylation of serine 
1179 and by AKT-dependent phosphorylation of serine 1177. (A) HUAECs kept 
untreated or exposed to flow were lyzed, and PKN2 was immunoprecipitated with a 
specific antibody. IgG served as a negative control. Shown are immunoblots of the 
lysate and the immunoprecipitate using anti-eNOS and anti-PKN2 antibodies. (B, C) 
Purified eNOS was incubated in kinase buffer without or with recombinant purified 
PKN2 together with 50 µM [γ-32P]-ATP (3000 Ci/mmol/L) (B) or ATP (C) for 30 minutes 
at 30°C. Thereafter samples were separated by SDS-PAGE. Shown are an 
autoradiogram and a Coomassie stain of the gel (B). Alternatively, an immunoblotting 
analysis was performed using antibodies recognizing eNOS and PKN2 protein or the 
eNOS S1177 and S1179 as well as PKN2 T816 phosphosites (C). (D) Model of the 








Figure 7. Endothelial PKN2 deficiency results in loss of flow-induced 
vasodilation and arterial hypertension. (A) Immunoblotting analysis of PKN1 and 
PKN2 expression in mouse lung endothelial cells (MLEC) from 8-week-old wild-type 
(WT) and induced EC-Pkn2-KO mice. (B) Effect of acetylcholine on the tone of 
mesenteric artery stripes from wild-type (WT) (n=7) and EC-Pkn2-KO animals (n=7) 
were determined after precontraction with 10 µM phenylephrine. (C) Mesenteric 
arteries isolated from tamoxifen-treated WT or EC-Pkn2-KO mice were precontracted 
with 100 nM of the thromboxane A2 analog U46619 and were then exposed to stepwise 
increases in perfusion flow. Flow-induced vasorelaxation is shown as percentage of 
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the passive vessel diameter (n=7 mice, WT and EC-Pkn2-KO). (D) Blood pressure in 
WT (n=12), EC-Pkn1-KO mice (n=8) and EC-Pkn2-KO (n=12) animals before, during 
and after induction of tamoxifen. Average blood pressure 3 days before induction was 
set to 100 %. The bar diagram shows systolic and diastolic arterial blood pressure 4 
days before tamoxifen treatment and in the second week after induction. (E) eNOS 
phosphorylation at S1176 and 1178 in lysates from mesenteric arteries prepared from 
tamoxifen-treated WT and EC-Pkn2-KO mice (n=3 animals). (F) Plasma nitrate and 
nitrite (NOx) levels in WT (n=7) and EC-Pkn2-KO mice (n=7) 10 days after induction. 
Data represent the mean ± SEM; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, (two-way ANOVA 
with Bonferroni’s post-hoc test (B and C), paired two-tailed Student’s t-test (D) or 
unpaired two-tailed Student’s t-test (F)). 
 
 
 
 
